Shanghai Shenqi Pharmaceutical Investment Management (SHSE:900904) Soars 15% This Week, Taking One-year Gains to 37%
Shanghai Shenqi Pharmaceutical Investment Management (SHSE:900904) Soars 15% This Week, Taking One-year Gains to 37%
If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost returns by picking market-beating companies to own shares in. For example, the Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:900904) share price is up 34% in the last 1 year, clearly besting the market decline of around 7.3% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Unfortunately the longer term returns are not so good, with the stock falling 11% in the last three years.
如果你想在股市增加财富,你可以通过购买指数基金来实现。但投资者可以通过选择表现优于市场的公司来持有股票,从而提高回报。例如,上海申奇医药投资管理有限公司。(上海证券交易所:900904)股价在过去1年上涨了34%,显然超过了市场跌幅约7.3%(不包括股息)。如果它能够长期保持这种优异的表现,投资者将会做得非常好!不幸的是,较长期的回报并不是那么好,该股在过去三年里下跌了11%。
On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.
在连续7天表现稳健的基础上,让我们来看看该公司的基本面在推动长期股东回报方面发挥了什么作用。
View our latest analysis for Shanghai Shenqi Pharmaceutical Investment Management
查看我们对上海申祺医药投资管理的最新分析
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
虽然市场是一种强大的定价机制,但股价反映的是投资者情绪,而不仅仅是潜在的企业表现。考察市场情绪如何随时间变化的一种方法是观察一家公司的股价和每股收益(EPS)之间的相互作用。
During the last year Shanghai Shenqi Pharmaceutical Investment Management grew its earnings per share, moving from a loss to a profit.
去年,上海申奇医药投资管理公司实现了每股收益的增长,实现了扭亏为盈。
We think the growth looks very prospective, so we're not surprised the market liked it too. Inflection points like this can be a great time to take a closer look at a company.
我们认为增长看起来非常有前景,所以市场也喜欢它,我们并不感到惊讶。像现在这样的拐点可能是仔细观察一家公司的好时机。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(在一段时间内)如下图所示(点击查看具体数字)。
It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. It might be well worthwhile taking a look at our free report on Shanghai Shenqi Pharmaceutical Investment Management's earnings, revenue and cash flow.
可能值得注意的是,首席执行官的薪酬低于类似规模公司的中位数。关注首席执行官的薪酬总是值得的,但更重要的问题是,该公司是否会在未来几年实现盈利增长。也许很值得一看我们的免费上海申奇医药投资管理公司收益、收入和现金流报告。
What About Dividends?
那股息呢?
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Shanghai Shenqi Pharmaceutical Investment Management the TSR over the last 1 year was 37%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence!
除了衡量股价回报外,投资者还应考虑总股东回报(TSR)。TSR包括任何剥离或贴现融资的价值,以及任何股息,基于股息再投资的假设。可以说,TSR更全面地描绘了一只股票产生的回报。我们注意到,上海申奇医药投资管理公司过去1年的总回报率为37%,好于上述股价回报率。而且,猜测股息支付在很大程度上解释了这种差异是没有好处的!
A Different Perspective
不同的视角
We're pleased to report that Shanghai Shenqi Pharmaceutical Investment Management shareholders have received a total shareholder return of 37% over one year. That's including the dividend. That certainly beats the loss of about 4% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Shanghai Shenqi Pharmaceutical Investment Management you should know about.
我们很高兴地报告,上海申奇医药投资管理公司的股东在一年的时间里获得了37%的总股东回报。这还包括股息。这当然超过了过去五年每年约4%的损失。我们通常更看重短期的长期表现,但最近的改善可能暗示着业务内部出现(积极的)拐点。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。例如,考虑一下风险。每家公司都有它们,我们已经发现上海申奇医药投资管理2个警示标志你应该知道。
We will like Shanghai Shenqi Pharmaceutical Investment Management better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我们看到一些大的内部收购,我们会更喜欢上海申奇医药投资管理公司。在我们等待的时候,看看这个免费最近有大量内幕收购的成长型公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CN exchanges.
请注意,本文引用的市场回报反映了目前在CN交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。